Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review

David L. Chan, Diego Ferone, Manuela Albertelli, Nick Pavlakis, Eva Segelov, Simron Singh

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background/Purpose: Somatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting. Methods: Eligible trials (using more than 30 mg octreotide or 120 mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively. Results: Eighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100%, but response rates were modest (at 0–14%). Rates of biochemical improvement (27–100%) and symptom improvement (23–100%) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues. Conclusions: The current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours.

LanguageEnglish
Pages366-375
Number of pages10
JournalEndocrine
Volume57
Issue number3
DOIs
StatePublished - Sep 2017

Keywords

  • Lanreotide
  • Neuroendocrine tumour
  • Octreotide
  • Somatostatin
  • SSA
  • Systematic review

Cite this

Chan, David L. ; Ferone, Diego ; Albertelli, Manuela ; Pavlakis, Nick ; Segelov, Eva ; Singh, Simron. / Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS : a systematic review. In: Endocrine. 2017 ; Vol. 57, No. 3. pp. 366-375
@article{f0220f2e56744313b612e256bc59f83f,
title = "Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review",
abstract = "Background/Purpose: Somatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting. Methods: Eligible trials (using more than 30 mg octreotide or 120 mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively. Results: Eighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100{\%}, but response rates were modest (at 0–14{\%}). Rates of biochemical improvement (27–100{\%}) and symptom improvement (23–100{\%}) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues. Conclusions: The current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours.",
keywords = "Lanreotide, Neuroendocrine tumour, Octreotide, Somatostatin, SSA, Systematic review",
author = "Chan, {David L.} and Diego Ferone and Manuela Albertelli and Nick Pavlakis and Eva Segelov and Simron Singh",
year = "2017",
month = "9",
doi = "10.1007/s12020-017-1360-z",
language = "English",
volume = "57",
pages = "366--375",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Springer-Verlag London Ltd.",
number = "3",

}

Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS : a systematic review. / Chan, David L.; Ferone, Diego; Albertelli, Manuela; Pavlakis, Nick; Segelov, Eva; Singh, Simron.

In: Endocrine, Vol. 57, No. 3, 09.2017, p. 366-375.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS

T2 - Endocrine

AU - Chan,David L.

AU - Ferone,Diego

AU - Albertelli,Manuela

AU - Pavlakis,Nick

AU - Segelov,Eva

AU - Singh,Simron

PY - 2017/9

Y1 - 2017/9

N2 - Background/Purpose: Somatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting. Methods: Eligible trials (using more than 30 mg octreotide or 120 mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively. Results: Eighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100%, but response rates were modest (at 0–14%). Rates of biochemical improvement (27–100%) and symptom improvement (23–100%) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues. Conclusions: The current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours.

AB - Background/Purpose: Somatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting. Methods: Eligible trials (using more than 30 mg octreotide or 120 mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively. Results: Eighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100%, but response rates were modest (at 0–14%). Rates of biochemical improvement (27–100%) and symptom improvement (23–100%) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues. Conclusions: The current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours.

KW - Lanreotide

KW - Neuroendocrine tumour

KW - Octreotide

KW - Somatostatin

KW - SSA

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85025094263&partnerID=8YFLogxK

U2 - 10.1007/s12020-017-1360-z

DO - 10.1007/s12020-017-1360-z

M3 - Article

VL - 57

SP - 366

EP - 375

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 3

ER -